Ibogaine Contraindications: Who Should Not Receive IV Ibogaine

Definition box

Definition: Ibogaine contraindications are medical situations where IV ibogaine infusion—intravenous psychoactive ibogaine under physician supervision—should not proceed, or should proceed only after specialist clearance that may still result in a hard stop. Because ibogaine can prolong the QTc interval, cardiac disease, long QT, unsafe electrolytes, and interacting medications are central exclusion themes. Evidence gap: Most published clinical safety signals (including Knuijver et al., *Addiction*, 2021) come from oral ibogaine HCl cohorts; they inform risk education but are not IV-psychoactive RCTs. Support IV (fluids, magnesium) ≠ psychoactive IV. Ibogaine is U.S. Schedule I and not FDA-approved. This page is educational screening literacy—not a personal clearance checklist.

Quotable answer (56 words)

Ibogaine contraindications center on cardiac and medical risk: prolonged QTc, unstable heart disease, unsafe electrolytes, and interacting drugs often exclude candidates. IV ibogaine infusion requires physician supervision and continuous monitoring. Most published safety observations still reflect oral ibogaine HCl. It is not FDA-approved; unsupervised use is dangerous. Individual clearance belongs to licensed clinicians.

Why “who should not” is the most important SEO page on this topic

Marketing pages sell transformation. Contraindication pages prevent funerals. Anyone researching who should not receive IV ibogaine should treat exclusion criteria as a feature of ethical care—not a sales obstacle.

This site’s entity is true psychoactive IV ibogaine infusion in a medical infusion setting (consult → cardiac screening → monitored infusion → integration). That journey only makes ethical sense when programs are willing to say no. Pair this article with /safety-and-screening and /blog/is-ibogaine-safe-screening-cardiac-risk.

Cardiac-first exclusion themes (educational)

These categories commonly appear in serious screening frameworks. They are not an exhaustive medical algorithm and do not replace physician judgment.

Often high-concern / potential hard stops

• Known long QT syndrome or baseline prolonged QTc on ECG
• Recent myocardial infarction, unstable angina, decompensated heart failure
• Clinically significant arrhythmia history (context-dependent)
• Uncorrected severe electrolyte abnormalities (especially low magnesium or potassium)
• Inability to complete continuous cardiac monitoring or emergency transfer plan

Medication and interaction themes

• Concurrent QT-prolonging medications without specialist review
• Unreviewed polypharmacy (psychotropics, antibiotics, antiemetics, methadone at certain risk profiles, etc.)
• Recent substance combinations that impair respiratory or cardiac stability

Broader medical / psychiatric themes often reviewed

• Severe hepatic impairment (ibogaine metabolism considerations; clinician judgment)
• Uncontrolled epilepsy or certain neurological risks
• Active psychosis or unstable severe psychiatric crisis where an intensive psychoactive session is unsafe
• Pregnancy (programs typically exclude; this is not obstetric advice)
• Inability to consent / lack of capacity

A clinic that cannot explain how it handles these themes is not ready for IV psychoactive care. Vetting: /blog/how-to-choose-an-ibogaine-clinic · Red flags: /blog/cheap-ibogaine-clinic-red-flags.

Why oral literature still matters for IV contraindications

Readers sometimes argue: “Those QTc papers were oral, so IV is different—ignore them.” That is backwards.

• Knuijver et al. (*Addiction*, 2021) showed clinically relevant QTc prolongation after oral ibogaine HCl in opioid-dependent patients—establishing a human cardiac risk signal that any route must respect.
• Cherian et al. (*Nature Medicine*, 2024) used oral ibogaine with IV magnesium in a carefully screened veteran cohort—illustrating that even research protocols treat electrolytes/cardiac risk as first-class citizens. That paper does not prove psychoactive IV ibogaine is safe or effective.
• Mosca et al. (*Current Neuropharmacology*) summarize cardiotoxicity concerns amid limited RCTs.

Route changes pharmacokinetics; it does not erase the need for ECG, telemetry, and exclusion discipline. Support IV magnesium is not a substitute for saying no to contraindicated candidates. See /blog/electrolytes-support-iv-vs-psychoactive-iv and /blog/ibogaine-oral-vs-iv.

Opioid detox candidates: extra caution, not automatic clearance

People seeking ibogaine for fentanyl/opioid withdrawal often have dehydration, sleep loss, polysubstance exposure, and medication complexity—factors that can worsen cardiac risk. Interest in withdrawal interruption does not override contraindications. Related: /ibogaine-for-addiction · /blog/ibogaine-for-fentanyl · /blog/ibogaine-vs-methadone · /blog/ibogaine-vs-suboxone.

Abruptly stopping methadone or Suboxone to “qualify” can itself create medical danger. Transitions belong with clinicians.

Depression / PTSD interest does not waive cardiac rules

Searches for mood or trauma benefits still confront the same QTc architecture. Open-label veteran research interest (oral + IV Mg in Cherian 2024) does not authorize skipping ECG for IV protocols. See /ibogaine-for-depression · /ibogaine-for-ptsd · /blog/stanford-ibogaine-mistic · /blog/ibogaine-treatment-resistant-depression.

What ethical screening looks like before IV infusion

1. Comprehensive history (cardiac, psychiatric, substance, medications)
2. ECG with QTc interpretation by qualified clinicians
3. Labs including electrolytes; other labs as indicated
4. Written documentation of psychoactive IV route vs oral + support IV
5. Continuous telemetry plan and emergency protocols
6. Willingness to cancel after deposit if new risk appears
7. Aftercare and—when opioids are involved—overdose planning

Process pages: /how-it-works · /what-is-ibogaine-infusion · Side effects literacy: /blog/ibogaine-side-effects.

Legal and regulatory note (not legal advice)

Ibogaine is Schedule I under U.S. federal law (21 CFR 1308.11) and is not FDA-approved. There is no FDA label list of contraindications for an approved ibogaine product—because there is no approved product. Clinics abroad still owe patients transparent medical exclusion standards. Not legal advice.

Soft CTA

If you are unsure whether medical criteria might exclude you, that uncertainty is a reason for a screening consult—not a reason to skip screening. Start with /safety-and-screening, then /apply. FAQ: /faq.

FAQ

Who should not receive IV ibogaine? People with significant cardiac risk (e.g., long QT / unsafe QTc, unstable heart disease), critical electrolyte problems, dangerous drug interactions, or other clinician-determined exclusions should not proceed. Final decisions belong to licensed physicians.

Are contraindications different for IV vs oral? Pharmacokinetics differ, but cardiac risk education from oral observational series still informs IV screening. Do not treat “IV” as a loophole around ECG.

Is prolonged QTc an absolute contraindication? Often treated as a major exclusion or hard stop pending specialist review. Individual thresholds are clinical judgments—not blog rules.

Does IV magnesium make contraindications irrelevant? No. IV magnesium in some **oral** research protocols is support—not a green light for contraindicated patients or proof of psychoactive IV safety.

Can I self-screen with a wearable ECG? Consumer devices are not a substitute for clinical ECG interpretation, labs, and physician oversight.

What if a cheap clinic skips ECG? Treat that as a red flag—see /blog/cheap-ibogaine-clinic-red-flags.

Is ibogaine FDA-approved with an official contraindication label? No. Not FDA-approved; Schedule I federally.

Where is the full safety hub? /safety-and-screening.

Medical disclaimer

Educational content only—not a diagnosis, clearance, or treatment plan. Ibogaine can cause life-threatening cardiac events. Do not self-administer. Seek licensed clinicians and emergency care when indicated.

Sources (selected)

1. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; clinically relevant QTc prolongation in opioid-dependent patients.
2. Mosca A. et al. *Current Neuropharmacology* — systematic review; cardiotoxicity concerns; limited RCTs.
3. Cherian K.N. et al. *Nature Medicine*. 2024 — oral ibogaine + IV magnesium (MISTIC); screened veteran cohort; not an IV-psychoactive safety RCT.
4. 21 CFR 1308.11 — Schedule I (ibogaine).